knowledge -WSS

knowledge

author：leisure time 2025-08-11 08:00:43 - browse：437

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： R1 RCM gets $5.8 billion buyout offer from private equity firm

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

A solution to the after

PBM reform efforts get punted in Congress

NIH study of ME/CFS points to clear biological hallmarks

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

focus

knowledge

focus

Supreme Court strikes down use of affirmative action

The Harvard botanist who searched for psychedelics in the Amazon

Hollywood unions extend contract negotiations for actors

Dario to buy mental health app maker Twill in cash and stock deal

Continuity nursing helped my family in our darkest PICU moments

Alabama hospital puts IVF treatments on hold

Drug repurposing or repositioning? The language matters

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

ChatGPT in medicine: STAT answers readers' burning questions

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

entertainment

Humana cuts profit projections as Medicare Advantage costs soar

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Test for long Covid? Researchers find new clue in blood samples

Dewpoint Therapeutics lays off staff after losing partnerships

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Parkinson’s finding may lead to tests and, someday, treatments

focus

knowledge

hotspot

hotspot